Glycodelin reduces breast cancer xenograft growth in vivo

20Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Malignant growth is characterized by loss of cell differentiation, uncontrolled proliferation and resistance to apoptosis. Many tumor suppressor genes that protect cells against malignant transformation regulate cell differentiation. Here, we show for the first time that glycodelin, a differentiation-related protein, reduces breast cancer tumor growth in vivo. We found that glycodelin cDNA-transfected MCF-7 breast cancer cells showed a differentiated phenotype and produced smaller tumors in mouse mammary fat pads compared with control-transfected cells. Glycodelin-induced differentiation was associated with reduced expression of oncogenes and increased expression of tumor suppressor genes. Our results suggest that glycodelin acts as a tumor suppressor in breast cancer. This may explain its reported association with a more favorable prognosis in some cancers. © 2008 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Hautala, L. C., Koistinen, R., Seppälä, M., Bützow, R., Stenman, U. H., Laakkonen, P., & Koistinen, H. (2008). Glycodelin reduces breast cancer xenograft growth in vivo. International Journal of Cancer, 123(10), 2279–2284. https://doi.org/10.1002/ijc.23773

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free